Safety Study of Prucalopride in Healthy Volunteers - Full Text View

Sponsored by:	Movetis
Information provided by:	Movetis
ClinicalTrials.gov Identifier:	NCT00793429

Purpose

In this study healthy volunteers received increasing doses of prucalopride to study the tolerability and cardiac safety of prucalopride. The study hypothesis was that prucalopride at doses up to 10 mg has no clinically relevant effect on the cardiovascular safety in healthy volunteers.

Condition	Intervention	Phase
Healthy	Drug: Prucalopride Other: Placebo	Phase I

Drug Information available for: Prucalopride

U.S. FDA Resources

Study Type:	Interventional
Official Title:	A Double-Blind, Placebo-Controlled, Two-Way Cross-Over in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Prucalopride at Steady-State

Further study details as provided by Movetis:

Detailed Description:

Single-centre, double-blind, placebo-controlled, cross-over study in 33 healthy volunteers with 2 sessions. Each session consisted of a run-in day for baseline assessments, 8 treatment days and 5 additional days for followup assessments. Subjects were randomised to start with either the prucalopride or placebo session. The prucalopride dose was consecutively escalated in 2 mg steps per day, starting from 2 mg up to 10 mg once daily If a subject did not tolerate the 10- or 8-mg dose, 1 step back in the dosage scheme was allowed, from 10 to 8 mg on Day 6, or from 8 to 6 mg on Day 5. Subjects with intolerance for doses of less than 6 mg, were withdrawn from the study. Repeated dosing (6, 8 or 10 mg) was continued once daily until Day 8, to achieve steady-state. During placebo, the number of placebo tablets was consecutively escalated in an identical way as described for prucalopride. Between the 2 sessions, there was a washout period of 14 to 21 days, to avoid any carry-over effect.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Aged between 18 and 45 years.
Normal weight.
Healthy on the basis of a pre-study physical examination, medical history, anamnesis,ECG, 24-hour Holter monitoring, echocardiogram and the results of blood biochemistry and haematology tests and a urinalysis carried out in 3 weeks preceding randomisation.

Exclusion Criteria:

History or suspicion of alcohol, barbiturate, amphetamine or narcotic abuse.
Smoking more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 6 months prior to selection.
History of cardiac arrhythmias, bronchospastic or cardiovascular disease (e.g. ischaemic heart disease or cerebrovascular accident), diabetes mellitus, thyrotoxicosis,Parkinsonism.
Presence of prolonged QTc (Bazett) on ECG at screening (QTc >450 ms in male subjects, QTc >470 ms in female subjects).
Use of concomitant medication, except for oral contraceptives and paracetamol.
Participation in an investigational drug study in 30 days prior to the first visit.
Donation of blood in the 60 days preceding the first visit.
Pregnancy or breast-feeding female.
Female subjects of childbearing potential without adequate contraceptive protection during the study.

Contacts and Locations

No Contacts or Locations Provided

More Information

Study ID Numbers:	GBR-9
Study First Received:	November 18, 2008
Last Updated:	November 20, 2008
ClinicalTrials.gov Identifier:	NCT00793429
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Movetis:

electrocardiographic safety
pharmacokinetics

Study placed in the following topic categories:

Healthy

ClinicalTrials.gov processed this record on January 15, 2009